Market Overview

JP Morgan Maintains Overweight on Omnicare After CEO Resignation

Related OCR
JP Morgan Downgrades Omnicare Following CVS Deal
Earnings Scheduled For July 24, 2015

JP Morgan has published a research report on Omincare (NYSE: OCR) commenting on today's announced management change.

In the report, JP Morgan writes, "This morning, Omnicare announced that the Board accepted John Figueroa's resignation as CEO and director. On the conference call, the company pointed to personal reasons as the driver behind Mr. Figueroa's decision to resign. While we were surprised by today's announcement, we view today's weakness as a buying opportunity. Importantly, the company indicated that the previously issued FY12 guidance remains unaffected. Further, we note that John Workman and Nitin Sahney, both of whom have been instrumental in crafting and executing the ongoing turnaround and strategy, are taking on larger roles within the company, which we view positively. As we've noted in the past, we believe the company remains well positioned to capitalize on strong industry fundamentals and realize incremental benefits from the turnaround."

JP Morgan maintains its Overweight rating on Omnicare, which is currently trading down $2.48 from Friday's $33.36 closing price.

Latest Ratings for OCR

Jul 2015JP MorganDowngradesOverweightNeutral
Jun 2015Goldman SachsDowngradesBuyNeutral
May 2015Cowen & Co.DowngradesOutperformMarket Perform

View More Analyst Ratings for OCR
View the Latest Analyst Ratings

Posted-In: John Figueroa JP MorganAnalyst Color News Reiteration Management Analyst Ratings


Related Articles (OCR)

View Comments and Join the Discussion!